ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each. Of course, a subscription is only $20/mo, so you may prefer to subscribe. If so, click on Subscribe in the menu.

Browse

All Products

Viewing all 5996 products

View All
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
Next

Visen Reports Successful Phase III Trial of Hypoparathyroidism Therapy

$5.00

BeiGene Opens $800 Million US Biologics Manufacturing Facility

$5.00

Amoytop to Run China Combo Trial of Aligos Hepatitis B Therapy

$5.00

Triastek Partners 3D Printing Drug Technology in $1.2 Billion Deal with BioNTech

$5.00

Samsung Bioepis’ Rare Disease Biosimilar Approved for US

$5.00

Renalys Raises $38.5 Million to Advance IbA Drug in Japan

$0.00

Gan & Lee’s GLP-1 Candidate Posts Solid Results for Weight Loss

$5.00

Artiva, a Spin-out from Korea’s GC Cell, Raises $167 Million in US IPO

$5.00

Innovent Reports Data from Phase III Trial of GLP-1R Candidate

$5.00

Rona Therapeutics Raises $35 Million to Develop Nucleic Acid Products

$5.00

Elpiscience Plans Hong Kong IPO to Support Novel Cancer Therapies

$5.00

AusperBio Raises $37 Million in Series A Round for Antisense Oligonucleotides

$5.00

Everest Files for Full Approval of IgA Nephropathy Therapy in China

$5.00

SK Acquires Rights to Radiopharmaceutical in $571 Million Agreement

$5.00

Fujirebio to Develop New Alzheimer’s Diagnostic for Use with AirBio AD Therapy

$5.00

Biocytogen Signs $325 Million Bispecific Discovery Pact with SOTIO

$5.00

Sino Biological Acquires Vancouver’s SignalChem Biotech for $48 Million

$5.00

Legend Biotech May Have Received a Takeover Bid; Stock Price Climbs

$5.00

Sichuan Biokin, Parent of SystImmune, Plans $500 Million IPO in Hong Kong

$5.00

Keymed Bio Out-licenses Global Rights for Two Bispecifics in $186 Million Deal

$5.00

Foreseen Bio Out-Licenses Novel ADC to Ipsen in $1 Billion Agreement

$5.00

Sanyou Bio Adds BioGeometry’s AI Antibody Design to its CRO Services

$5.00

Genexine to Acquire EPD Bio, a Protein Degrader Startup, for $180 Million in Stock

$5.00

Zhiyi Bio Says Live Biotherapeutic for Diarrhea Passes Safety Test

$5.00

The US Speaker of the House Vows Congress will Vote on the Biosecure Act in 2024

$5.00

Hinova Details Progress of Candidate for AR+ Triple-Negative Breast Cancer

$5.00

AusperBio Reports on Antisense Oligonucleotide that Targets HBV mRNA

$5.00

Takeda Discloses that Ascentage Deal Worth up to $1.2 Billion in Milestones

$5.00

IASO Acquires Innovent’s Share of BCMA CAR-T in Exchange for 18% of IASO

$5.00

Tanvex, a Taiwan Biotech, Approved to Market Neupogen Biosimilar in the US

$5.00

Hasten Biopharma In-licenses Pan-Asia Distribution Rights for 14 Products

$5.00

Samsung Bio Signs $1 Billion Manufacturing Agreement with US Pharma

$5.00

HiRO Adds New Jersey’s DeltaMed Solutions to its Portfolio of CROs

$5.00

Eisai Plans to Speed Development of ADC After BMS Returns Rights

$5.00

CASI Pharma’s CEO Offers $40 Million to Take Company Private

$5.00

Innovent Says GLP-1R/GCGR Reduces Liver Fat and Improves Metabolic Health

$5.00

Novo Nordisk’s Wegovy Approved in China, But Patent Expires in Two Years

$5.00

Simcere Zaiming Approved to Launch Novel EGFR for Metastatic Colorectal Cancer

$5.00

Gan & Lee Says GLP-1 Candidate Offers Strong Weight Loss in Early Trial

$5.00

AprilBio Out-Licenses Rights for IL-18 Candidate to California’s Evommune

$5.00

Fosun Pharma Sells 5% Stake in India’s Gland Pharma for $172 Million

$5.00

Rapafusyn Pharma Raises $28 Million for Molecular Glues from China Investors

$5.00

MabCare Out-Licenses PTK7 ADC to Day One Biopharma in $1.2 Billion Deal

$5.00

Ronovo Surgical Raises $44 Million to Commercialize Carina™ Surgical Robotic System

$5.00

YolTech Out-Licenses China Rights for CRISPR/Cas Editor to KACTUS

$5.00

Starna and Recorna Team Up to Discover RNA Drugs for Lung Diseases

$5.00

Asieris Says ReviR Identifies Candidates to Modulate Oncogenic Driver Gene

$5.00

XtalPi Stages $127 Million IPO in Hong Kong for AI Drug Discovery

$5.00

XtalPi Stages $127 Million IPO in Hong Kong for AI Drug Discovery

$5.00

Takeda Signs $100 Million Option for Ascentage’s Lead TKI Therapy

$5.00

Nanjing Biosion Reports anti-TSLP mAb Effective for Atopic Dermatitis

$5.00

Asia Scientific Global Details Plans to Develop Inhaled Forms of Existing Drugs

$5.00

Shionogi Options Two Hearing Loss Therapies in Deal Worth 415 Million Euros

$5.00

Junshi Bio Reports Tuoyi Meets Endpoints in Liver Cancer Clinical Trial

$5.00

Kyowa Kirin Plans $530 Million Biologic Manufacturing Plant in US

$5.00

Ascentage Approved to Begin China Phase III Trial of SDH-deficient GIST

$5.00

Zymeworks’ HER2 Bispecific Under Review in China for Rare HER2 Cancers

$5.00

Structure Posts Positive Obesity Drug Results; Raises $476 Million

$5.00

SCG Cell Therapy Posts Solid Results for HBV T Cell Therapy

$5.00

Alphamab Forms $615.5 Million Drug Development Pact with ArriVent

$5.00

I-Mab’s Bispecific Antibody Joined by BMS’s PD-1 in Gastric Cancer Trial

$5.00

Ascentage Reports 91% Response Rate for Bcl-2 Inhibitor in WM

$5.00

AbelZeta Says CAR-T Shows Efficacy in Hepatocellular Carcinoma Patients

$5.00

Leads’ Bispecific Effective in Extrapulmonary Neuroendocrine Carcinomas

$5.00

RemeGen Says ADC Successfully Targets Mesothelin in Solid Tumors

$5.00

Summit Expands Rights for Akeso’s PD-1/VEGF Bispecific in $70 Million Agreement

$5.00

US Congress Members Allege GenScript Controlled by China Communist Party

$5.00

Akeso Says PD-1/VEGF Candidate Out-Performs Keytruda in NSCLC

$5.00

Gyre Therapeutics Green-Lighted for China Trials of Pulmonary Drug

$5.00

Burning Rock to Develop Diagnostic Assays for Bayer’s Precision Drugs

$5.00

Bio-Thera Out-licenses EU Rights for Arthritis Biosimilar in $157 Million Deal

$5.00

HuidaGene Partners Use of CRISPR nuclease (hfCas12Max) with Synthego

$5.00

Japan’s Asahi Kasei in $1.1 Billion Deal to Acquire Calliditas

$5.00

MediLink Inks $1.8 Billion Deal to Develop New ADC’s for BioNTech

$5.00

CStone Sells Central Europe Marketing Rights for PD-L1 to Ewopharma

$5.00

CStone Reports Positive Early Results from Phase I Trial of ROR1 ADC

$5.00

Tyligand Starts US Trial of KRAS G12D Inhibitor for Solid Tumor Cancers

$5.00

Degron Partners Molecular Glue Degraders with Takeda in $1.2 Billion Deal

$5.00

Nona Bio Signs $604 Million License to Discover mAbs for AstraZeneca

$5.00

AstraZeneca Says China is Important Source for Innovative Drug Development

$5.00

Innovent’s IGF-1R Antibody NDA Under China Review for Thyroid Eye Disease

$5.00

RemeGen Completes Enrollment in Two Phase III Trials for Autoimmune Diseases

$5.00

Hengrui Sells GLP-1 Portfolio Rights to Startup in $6 Billion Deal

$5.00

AstraZeneca Plans $1.5 Billion ADC Manufacturing Plant in Singapore

$5.00

Erasca In-licenses Two China RAS Candidates in Two Deals Worth $349 Million

$5.00

Eisai Expects Big Improvement in Sales for Alzheimer’s Therapy in 2024

$5.00

Beimei Pharma In-licenses Acne Therapy from Sol-Gel in $15 Million Deal

$5.00

InnoCare Completes Phase II Enrollment of TYK2 Inhibitor for Psoriasis

$5.00

Takeda to Option Alzheimer’s Therapy from AC Immune in $2.2 Billion Deal

$5.00

Ractigen Says China IND Approved for siRNA Candidate that Targets ALS

$5.00

Everest Begins Commercialization of Nefecon, an IgA Nephropathy Therapy

$5.00

Single-Cell Analysis Shows Efficacy of IASO’s BCMA CAR T in Autoimmune Disease

$5.00

Zai Lab Approved to Launch Augtyro in China for NSCLC with ROS1 Mutation

$5.00

Mabwell’s Nectin-4 ADC Shows Efficacy in Triple-Negative Breast Cancer

$5.00

Ribobay Builds Shanghai Oligonucleotide Plant using Cytiva’s FlexFactory

$5.00

WestGene to Start US Trials of EB Virus-Related mRNA Therapeutic Cancer Vaccine

$5.00

BIO Survey: 74% of Western Biopharmas Would Be Affected by WuXi AppTec Ban

$5.00

Innovent Says GLP-1/GCGR Dual Therapy Showed Better T2D Results and Weight Loss

$5.00

NeuShen Doses First Patient in Trial for Novel Schizophrenia Therapy

$5.00

Sciwind Biosciences Out-licenses Korean Rights for GLP-1 to HK inno.N

$5.00

Sciwind Biosciences Out-licenses Korean Rights for GLP-1 to HK inno.N

$5.00

Bio-Gene Technologies Starts China Trial of CAR-T for Leukemia

$5.00

Sino Biological Pays $48 Million to Acquire Vancouver’s SignalChem

$5.00

Biocytogen Signs Evaluation/Licensing Agreement for TCR-mimic with BioCopy

$5.00

Leads Biolabs Begins Phase III Trial of PD-L1/4-1BB Bispecific for Solid Tumors

$5.00

Eluminex Starts Trials of Novel Trispecific Fusion mAb for Macular Edema

$5.00

SCG and A*STAR to Develop better Stem Cell Manufacturing in Singapore

$5.00

WuXi AppTec Says Q1 Revenues Hit Targets, Clients not Leaving Company

$5.00

Brise Pharma Closes $20 Million in A Rounds for Novel Pain Drugs

$5.00

Transcenta and Agilent Collaborate on Companion Diagnostic for Claudin18.2 mAb

$5.00

YS Biopharma Says PIKA Rabies Vaccine Effective after One-Week Dosing

$5.00

Abbisko Completes Enrollment in Global Phase III Trial for Tenosynovial Giant Cell Tumor

$5.00

Kelun/Merck Release Positive Early Data on TROP-2 ADC for Gastric Cancer

$5.00

Kexing Biopharm’s Phase III Trial of Inhaled RSV Therapy for Children

$5.00

VesiCURE Says Stem Cell Derived Extracellular Vesicles Effective in UC

$5.00

Sino Biopharm to Partner China Development of Boehringer Ingelheim Portfolio

$5.00

Junshi's Eighth China Approval of PD-1 is for Renal Cell Carcinoma

$5.00

D3 Bio Raises $62 Million in Series A+ Round for Next-Gen KRAS G12C Inhibitor

$5.00

Visen Pharma Plans Hong Kong IPO to Support Endocrine Therapies

$5.00

Aurisco Pharma Expands Yangzhou CRDMO Facility for Generic GLP-1 Peptides

$5.00

Insilico Medicine, an AI Drug Company, Files for Hong Kong IPO

$5.00

RemeGen Granted US Fast Track for Dual-Target Candidate in Sjögren's Syndrome

$5.00

ProfoundBio, a Seattle-Suzhou ADC Company, Acquired by Genmab for $1.8 Billion

$5.00

Innovent and HutchMed File Combination Therapy NDA for Endometrial Cancer

$5.00

PharmaEssentia Publishes Results for Polycythemia Vera Therapy

$5.00

CMS Acquires JAK1 Inhibitor from Incyte for Autoimmune/Dermatology Diseases

$5.00

WuXi AppTec Passed Client Data to China Officials, Reuters Says

$5.00

InnoCare Doses First Patient in Combination Trial of SHP2 Inhibitor

$5.00

Sperogenix Files for Approval of Duchenne Muscular Dystrophy Therapy in China

$5.00

GenFleet Starts Combo Trial of CDK9 Inhibitor with BeiGene’s BTK Inhibitor

$5.00

Avenzo, Alleron's Partner, Raises $150 Million to Develop Their Partnered Cancer Drug

$5.00

Biocytogen Signs BiSpecific ADC Discovery Deal with Korea’s ABL Bio

$5.00

Biocytogen Signs BiSpecific ADC Discovery Deal with Korea’s ABL Bio

$5.00

Bio-Thera Cleared for US Trial of FRα ADC for Solid Tumor Cancers

$5.00

AriBio Out-Licenses China Rights To Alzheimer’s Candidate in $770 Million Deal

$5.00

Alphamab Publishes Trial Data on Bispecific for Non-Small Cell Lung Cancer

$5.00

WuXi Biologics Begins Construction of $1.4 Billion Singapore CRDMO Facility

$5.00

Merck KGaA to Build $326 Million Bioprocessing Production Center in Korea

$5.00

Novo Nordisk Invests $556 Million In Tianjin Manufacturing Plant for Weight Loss Drug

$5.00

Antengene Starts Dose Expansion in Trial of Claudin 18.2 ADC

$5.00

WuXi AppTec Reports 2023 Results; US Biopharmas Are 65% of Its Business

$5.00

Innovent Reports Positive Data from Phase II Trials of nAMD Therapy

$5.00

BeiGene PD-(L)1 Inhibitor Approved in US for Esophageal Carcinoma

$5.00

KeChow Approved to Launch Tunlametinib for Melanoma Patients in China

$5.00

Boehringer Options Schizophrenia Candidate from Japan’s Sosei in $822 Million Deal

$5.00

Hansoh Adds Global Rights for Zhuhai’s Bispecific in $700 Million Deal

$5.00

PegBio Plans Hong Kong IPO to Support Long Acting GLP-1 for Diabetes/Obesity

$5.00

Aslan Pharma Offers Data Showing Eblasakimab Effective in COPD

$5.00

Ranok to Start China Trial of Protein Degrader for Solid Tumors and Lymphomas

$5.00

RemeGen Says anti-HER2 ADC Effective for Cervical Cancer

$5.00

EurekaBio Raises $40 Million for New Lentiviral Vector Production System

$5.00

Zylox-Tonbridge Acquires China Rights to Vascular Devices for $15 Million

$5.00

Chengdu Maxvax Bio Raises $40 Million for Vaccines and Immunotherapies

$5.00

Chengdu Maxvax Bio Raises $40 Million for Vaccines and Immunotherapies

$5.00

Akeso Starts China Phase III Trial of PD-1/CTLA-4 Bispecific for NSCLC

$5.00

TransThera to Start European Arm of Global Trial for Bile Tube Cancer

$5.00

Innovent/AnHeart File China NDA for ROS1 Inhibitor to Treat NSCLC

$5.00

Haihe Out-Licenses Japan/Asia Rights for NSCLC Therapy to Taiho Pharma

$5.00

Qilu Says PD-1/CTLA-4 Combo Effective Against Cervical Cancer

$5.00

CARsgen Approved to Launch BMA CAR-T in China for Multiple Myeloma

$5.00

Innovent Starts Trials of Bispecific Antibody for Severe Asthma

$5.00

Mabwell Out-Licenses Rare Disease Therapy to Disc in $412 Million Deal

$5.00

AstraZeneca to Build Global Strategic Center in Shanghai

$5.00

Biotheus to Develop Antibodies With Bitterroot for Cardio-Immunology

$5.00

AstraZeneca to Continue Roxadustat Sales in China; Returns Other Rights

$5.00

Everest Medicines Approved to Start China Phase IIb Trial of Lupus Therapy

$5.00

Nhwa to Distribute Teva’s Movement Disorder Therapies in China

$5.00

BioCity Completes Enrollment of ETA Agonist Trial in Patients with IgA Nephropathy

$5.00

Longbio of Suzhou Says LP-003 Effective in Patients with Allergic Rhinitis

$5.00

CHMP Recommends Approval of Legend’s CAR-T as Second-Line Multiple Myeloma Therapy

$5.00

Immunofoco to Start US Trial of CAR-T for Gastrointestinal Tumors

$5.00

Simcere Announces Positive Data from Phase III Trial of Dual-Drug Oral Therapy for Stroke

$5.00

Innovent’s IGF-1R Antibody Meets Endpoint for Thyroid Eye Disease

$5.00

AlphaGen and ArtBio Form China-US Partnership for Radioligand Therapies

$5.00

Mabwell OK’d to Begin US Clinical Trials of ADC for Solid Tumors

$5.00

Biocytogen Signs Three-Year Antibody Discovery Pact with Gilead Sciences

$5.00

Jacobio to Start Phase III Trial of Novel Combination in NSCLC with KRAS G12C Mutations

$5.00

CASI Launches Pralatrexate in China for R/R Peripheral T-cell Lymphoma

$5.00

AusperBio Updates Clinical Progress of Antisense Oligonucleotide Therapy for HBV

$5.00

LianBio to Shut Down Operations; Will Distribute $528 Million to Shareholders

$5.00

Chugai Pharma Approved for China Launch of Complement Inhibitor 5 for NPH

$5.00

Yiviva Signs MOU with AstraZeneca to Develop New Drugs based on TCM Therapies

$5.00

Hengrui Launches Antifungal in China for Vulvovaginal Candidiasis

$5.00

Bayer Signs Letter of Intent to Market Trinity’s Glucose Monitor in China and India

$5.00

Eisai Launches Leqembi, an Alzheimer’s Drug, in China for Early-Stage Disease

$5.00

China Medical System Acquires China Rights to Phosphate Binder from Winhealth

$5.00

I-Mab Divests China Operations to Become Fully US-Based Biopharma

$5.00

Innovent Says NDA for Dual Agonist Obesity Therapy Accepted for China Review

$5.00

Wuhan iRegene Therapeutics Starts China Trial of iPSC Cell Therapy for Parkinson’s

$5.00

Fermion OK’d to Start China Trials of Novel JAK inhibitor for Autoimmune Diseases

$5.00

Anbogen Raises $12.5 Million to Develop Precision Oncology Portfolio

$5.00

Sirius Starts Phase I Trial in Australia of siRNA Aimed at Thromboembolic Disorders

$5.00

Inmagene Exercises Option for Two HutchMed Candidates in $460 Million Deal

$5.00

Biosyngen Nabs US Fast Track Status for TIL Cell Therapy in Liver Cancer

$5.00

Sanofi Invests in Graviton and its Lead Product, a ROCK2 Inhibitor in-licensed from Beijing Tide

$5.00

Biosion Cleared to Start US Trials of Novel anti-SIRPα mAb for Solid Tumor Cancers

$5.00

DualityBio and BioNTech announce US Fast Track Status for ADC in Ovarian Cancer

$5.00

US Legislators Target WuXi Bio and BGI; Aim to Prevent Transfer of US Genomic Data

$5.00

Data from Qilu Pharma’s Approved ALK Inhibitor for NSCLC Published in Journal

$5.00

Gracell Approved for US Trial of FasTCAR in Early Multiple Myeloma

$5.00

Vesicure Announces Positive Early Results of Exosome Technology for siRNA Delivery

$5.00

ArriVent Completes $175 Million NASDAQ IPO to Bring Assets from China to the US

$5.00

Jiuzhou Pharma Earmarks $42 Million for New CDMO Site in Japan

$5.00

Refreshgene’s siRNA Therapy Enables Children with Genetic Deafness to Hear

$5.00

Alphamab and 3D Medicines Out-License PD-L1 to India’s Glenmark

$5.00

Biocytogen Launches New Division to Partner Antibodies and License Mice Platforms

$5.00

Guangzhou’s Baird Medical Completes its First Thyroid Microwave Ablation in the US

$5.00

Duality and BioNTech Start China Arm of Phase III Trial of ADC for HER2 Breast Cancer

$5.00

InnoCare Launches Early Access to CD19 Immunotherapy in China for B-cell Lymphoma

$5.00

SineuGene Reports Positive Initial Results of RNA Therapy for ALS

$5.00

AstraZeneca Signs $26.5 Million Deal to Build Production Line in China for Type-2 Diabetes Drug

$5.00

CARsgen Cleared to Stage China Trial of CAR-T for Hepatocellular Carcinoma

$5.00

Lee’s Pharma in $138 Million Deal for China Rights to Heart Failure Treatment

$5.00

Adagene Reports Positive Early Results from its anti-CTLA-4 for Colorectal Cancer

$5.00

Chipscreen NewWay Starts China Trial of PD-1/CD40 Bispecific for Solid Tumor Cancers

$5.00

Henlius In-licenses Novel ESR1 Antagonist Therapy for Breast Cancer in $58 Million Deal

$5.00

WuXi Biologics to Discover mAbs for BioNTech for $20 Million Upfront

$5.00

GSK Pays $1.4 Billion to Acquire Aiolos, which In-Licensed a Hengrui Asthma Candidate

$5.00

Bayer Joins $162 Million Round for Ji Xing; Has Preferential Rights for In-Licensings

$5.00

OnCusp Completes $100 Million Series A Round for In-Licensed Cancer Candidates

$5.00

Kanghua Out-Licenses Norovirus Vaccine Candidate to HilleVax in $270 Million Deal

$5.00

Insilico Sells Global Rights for KAT6A Inhibitor to Menarini in $500 Million Deal

$5.00

Argo Signs $4.2 Billion Agreement Selling Four RNA Candidates to Novartis

$5.00

Tenacia Acquires China Rights to Tremor Therapy from Praxis in $279 Million Deal

$5.00

Biocytogen Sells Option for HER2/TROP2 Bispecific ADC to Radiance Biopharma

$6.00

Avistone Closes $140 million Series B Round for Precision Medicine Oncology Portfolio

$5.00

Novartis Acquires SanReno Therapeutics, a Shanghai Company with Two IgAN Candidates

$5.00

Allorion Out-Licenses ex-China Rights for CDK2 Inhibitor to Avenzo in $1 Billion Deal

$5.00

IASO and Umoja Partner to Develop Off-the-Shelf CAR-T Gene Therapies

$5.00

Ribo Life Science Forms $2 Billion siRNA Collaboration with Boehringer Ingelheim

$5.00

Belief BioMed Starts China Registrational Trial of Gene Therapy for Hemophilia A

$5.00

JW Therapeutics Extends Development Collaboration with 2seventy for Autoimmune CAR-T

$5.00

Elpiscience Out-licenses Bispecific Macrophage Engage to Astellas in $1.7 Billion Deal

$5.00

Qilu In-Licenses siRNA Targeting PCSK9 from Ribo in $100 Million Agreement

$5.00

Innovent Will Trial its PD-1 With Xuanzhu’s HER-2 ADC for Solid Tumor Cancers

$5.00

Innovent And Sanegene Collaborate to Develop siRNA for Hypertension

$5.00

Biocytogen and CtM Biotech Identify Tri-Specific T Cell Engager for Cancers

$5.00

Gracell, a CAR-T Company, to be Acquired by AstraZeneca for $1.2 Billion

$5.00

LianBio Sells China Rights for Radioenhanced Drug to Janssen for $30 Million

$5.00

Huadong to Promote Impact’s PARP Inhibitor in China in $40 Million Agreement

$5.00

Ablaze Medicine Partners with Oncoshot for AI-based Optimization of Clinical Trials

$5.00

CStone Sells China Rights for IDH1 Inhibitor to Servier Pharma for $50 Million

$5.00

CellOrigin Starts China Trial of Macrophage-based CAR Therapy

$5.00

GSK Acquires ex-China Rights to Second ADC from Hansoh in $1.7 Billion Deal

$5.00

InxMed Licenses Rights to Escugen’s Linker-Payload Platform for ADC Candidates

$5.00

RNAimmune Approved to Start US Trials of mRNA Vaccine for RSV

$5.00

Nona Out-licenses MSLN-targeting ADC to Pfizer in $1 Billion Agreement

$5.00

GeneQuantum and BioMap Form AI Collaboration to Discover Novel ADC Candidates

$5.00

Fosun Pharma Receives Support for Phase III Trial of Triple Artemisinin Therapy for Malaria

$5.00

Alebund Reports Positive Phase II Data for Novel Therapy Aimed at Dialysis Side Effects

$5.00

Evive and Nona Partner Up to Develop Antibody Drugs

$5.00

SystImmune Out-Licenses Rights for ADC to BMS in $8.4 Billion Agreement

$5.00

Connect Reports Positive Data from Phase IIb Trial of IL-4Rα Inhibitor for Asthma

$5.00

Yingli Reports Positive Data from Phase III Trial of Linperlisib for T-cell Lymphoma

$5.00

Xtalpi, a Quantum Physics-AI Drug Discovery Company, Files for Hong Kong IPO

$5.00

AbelZeta Forms a China CAR-T Collaboration with AstraZeneca

$5.00

Aspen Pharma Buys Sandoz’s China Operations for $120 Million

$5.00

Innovent Adds Second ADC to Collaboration with Synaffix, an ADC CRO

$5.00

Adcentrx Adds $13 Million to A+ Round for Novel Antibody Drug Conjugates

$5.00

Ractigen Files to Start Australian Trials of saRNA Therapy for Bladder Cancer

$5.00

Singapore’s CytoMed Plans to Start Investigator Initiated Trials in China of Novel T Cell Therapies

$5.00

Abbisko Sells China Rights for CSF-1R Inhibitor to Germany’s Merck in a $605 Million Agreement

$5.00

WuXi Biologics’ Stock Price Falls 24% after Company Reduces H2 Revenue Estimate

$5.00

Perpetual Raises $8 Million in Seed Financing for AI Discovery of Novel Peptides

$5.00

Coherus Sets US Price of Junshi-Developed PD-1 at 20% Discount to Merck’s Keytruda

$5.00

GenFleet Reports KRAS G12C Inhibitor is Under Review in China for NSCLC Approval

$5.00

Accutar to Apply its AI Platform to Discover Inflammatory Disease Therapies with Evommune

$5.00

Everest Approved to Launch Nefecon in China for Rare Kidney Disease

$5.00

Korea’s DxVx Plans Novel Cancer Vaccine In-licensing from its Partner Oxford Vacmedix

$5.00

Gracell to Start US Phase I/II Trial of Lead CAR-T for Lupus

$5.00

Zhifei Biological to Acquire Chongqing Chenan Bio, a Diabetes/Obesity Company

$5.00

AstraZeneca to Build Hong Kong R&D Center for Cell and Gene Therapies

$5.00

Usynova Out-Licenses KRASG12D Inhibitor to AstraZeneca in $419 Million Agreement

$5.00

Myriex Bio Acquires Antibody for Novel ADCs Discovered by WuXi Biologics

$5.00

BeiGene Acquires Global Rights to CDK2 Inhibitor from Ensem in $1.3 Billion Deal

$5.00

Simcere Signs $141 Million Deal for Connect Bio’s Novel Atopic Dermatitis Therapy

$5.00

Porton Advanced and Ascle Therapeutics Collaborate on CAR-NK Cell Therapy

$5.00

Haisco Out-Licenses Global Ex-China Rights for Bronchiectasis Therapy to Italy’s Chiesi Farma

$5.00

WuXi XDC Raises $520 Million in IPO; Climbs 39% in First Trading Session

$5.00

SciClone Acquires China Rights to Metastatic Breast Cancer Drug from Menarini

$5.00

Avistone Biotech Approved to Launch c-Met Inhibitor for NSCLC with Mutations

$5.00

Gritgen’s Gene Therapy for Hemophilia 100% Effective in IIT Trial

$5.00

ChromX Forms Diagnostic Collaboration with Boehringer Ingelheim for Lung Fibrosis

$5.00

AriBio of South Korea Expands Phase III Trial of Alzheimer’s Therapy

$5.00

Nona Collaborates with GeneQuantum to Offer Bioconjugate CMO Discovery Services

$5.00

Viatris and Theravance Report COPD Therapy Effective in China Phase III Trial

$5.00

Legend Signs $1.2 Billion Agreement Selling Global DLL3 CAR-T Rights to Novartis

$5.00

AnchorDx and DiaCarta Team Up to Develop Early Cancer Screening Diagnostics

$5.00

Sirius Files for Australian Trials of siRNA for Thromboembolic Disorders

$5.00

Eccogene Signs $2 Billion Deal Selling Rights for GLP-1 Agonist to AstraZeneca

$5.00

Porton Partners with BioMap for AI Based Gene Therapy Development

$5.00

Lerna Biopharma to Present New siRNA Therapy for Liver Failure

$5.00

WuXi XDC, an ADC/Bioconjugates CRDMO, Stages $500 Million IPO

$5.00

Celest Therapeutics Acquires Novel CAR-NK Cell Therapy from Senti Bio in $156 Million Deal

$5.00

Chipscreen Approved to Start China Trials for Novel Oral Psoriasis Therapy

$5.00

Mellow Hope and Rational Vaccines Join to Develop Herpes Simplex Vaccines

$5.00

Innovent Says GLP-1R/GCGR Dual Agonist Lowers Body Weight by 18.6%

$5.00

CStone Out-Licenses China Rights for anti-PD-1 to 3SBio for $22 Million

$5.00

HuidaGene Doses First Patient in Gene Therapy Trial for Inherited Blindness

$5.00

BioLineRx in $270 Million Deal for China Rights for Stem Cell Mobilizer

$5.00

AnHeart Sells Japanese Rights for ROS1 TKI to Nippon Kayaku for $40 Million Upfront

$5.00

Hengrui Sells PARP1 Inhibitor to Germany’s Merck in $1.7 Billion Deal

$5.00

Henlius Signs $200 Million Deal with Intas for EU/Indian Rights to its Anti-PD-1

$5.00

Angita Closes $46 Million Series B Extension for Musculoskeletal Disease Therapies

$5.00

Kelun-Biotech Releases Positive Data from TROP-2 ADC in Metastatic Breast Cancer

$5.00

LianBio Sells China Rights to Cardiovascular Drug for $350 Million to BMS

$5.00

OrbiMed Raises $751 Million for Asia Healthcare Fund; $3.6 Billion for Two Other Funds

$5.00

Aiolos Raises $245 Million; Partners Hengrui’s Asthma Drug in $1 Billion Deal

$5.00

Sirius Raises $60 Million for Cardiovascular siRNA Portfolio

$5.00

Hansoh Out-Licenses ADC to GSK in $1.6 Billion Deal

$5.00

AnHeart Says ROS1 Inhibitor Effective for NSCLC in Phase II Trial

$5.00

BeiGene Reports anti-PD-1 Effective in Phase III Trial for Gastric Cancers

$5.00

Ascentage Starts China Phase III trial of TKI for Leukemia

$5.00

Skyline Approved to Start China Trials of Gene Therapy for Macular Degeneration

$5.00

Belief BioMed Signs up Takeda to Commercialize Gene Therapy for Hemophilia in China

$5.00

KBP Sells Hypertension Candidate for $1.3 Billion to Novo Nordisk

$5.00

Hengrui Out-Licenses its PD-1 for Liver Cancer to Elevar in $1 Billion Deal

$5.00

WuXi Biologics’ Novel Bioprocessing Platform Offers Higher Yields, Lower Costs

$5.00

EpimAb Out-licenses Use of its Bispecific Platform to Almirall in $210 Million Agreement

$5.00

SparX’s Lead Claudin 18.2 mAb Candidate Included in CAR-iNKT Cell Therapy

$5.00

Ascentage Pharma to Start Phase III Trial of Bcl-2 Inhibitor for Leukemia

$5.00

Akeso Reports Positive Data from PD-1/CTLA-4 Bispecific Published in Lancet

$5.00

MediLink Out-Licenses Novel HER3 ADC to BioNTech in $1.1 Billion Agreement

$5.00

Kintor Approved to Begin China Phase II Trial for Pulmonary Fibrosis Candidate

$5.00

Gritgen Advances Hemophilia A Gene Therapy; Completes Manufacturing Plant

$5.00

I-Mab and ABL Bio Report Preliminary Efficacy of Bispecific PD-L1/4-1BB

$5.00

Beijing’s BioMap, an AI Drug Discovery Startup, Signs $1 Billion Deal with Sanofi

$5.00

GenFleet Starts Phase Ib/II Trial of CDK9 Inhibitor for Peripheral T-Cell Lymphomas

$5.00

Zeifei Biological Partners with GSK to Market Shingles Vaccine in China

$5.00

Jiangsu Atom Bio Begins Global Phase IIb/III Trial of Gout Treatment

$5.00

QYuns, an Autoimmune/Allergic Disease Biotech, Files for Hong Kong IPO

$5.00

Everest Medicine Says Kidney Disease Therapy Effective in Asian Patients

$5.00

Transcenta Cleared to Proceed in a US Phase III Trial of CLDN18.2 Antibody

$5.00

Arctic Vision Completes China Phase III Enrollment for Macular Edema Candidate

$5.00

PharmaEssentia Acquires Myeloid Immune Checkpoint Antibody from WuXi Biologics

$5.00

Magpie Pharma Reports Results from Phase II Trial of ALS Therapy

$5.00

Adlai Nortye Closes $97.5 Million Nasdaq IPO, Drops 27% Lower in Trading

$5.00

BioCity Plans Trial of TIM-3 mAb with AstraZeneca’s PD-L1 for Liver Cancer

$5.00

AffaMed Approved to Begin China Phase III Trial of Candidate for Dry AMD

$5.00

RemeGen Says Dual Targeted B-Cell Drug Meets Endpoints for Rheumatoid Arthritis

$5.00

Gracell Reports 100% Minimal Residual Disease Rate for CAR-T in Myeloma Trial

$5.00

Ascletis Enrolls 120 Patients for Phase III Trial of Glioblastoma Candidate

$5.00

Elpiscience Starts Australian Trial of Anti-Immunosuppressive Candidate

$5.00

I-Mab Says AbbVie Returns Rights for CD47, Ending $2 Billion Partnership

$5.00

Qihan Biotech Raises $16 Million for Gene-Edited Stem Cell Products

$5.00

Chime Enters Cooperation with Panolos to Develop Multi-Specific Candidate

$5.00

Tonghua Dongbao Out-Licenses US Rights for Three Insulin Biosimilars to Meitheal

$5.00

Everest Acquires China Rights to Lupus Nephritis Candidate in $132 Million Agreement

$5.00

Lynk Closes $16 Million C2 Round to Advance JAK Inhibitors for Autoimmune Diseases

$5.00

Asieris Says Drug-Device Combination Effective for Cervical Lesions

$5.00

AffaMed Begins China Phase III Trial of Therapy for Cataract Surgery Pain

$5.00

Novartis Ends $2.2 Billion Global PD-1 Partnership with BeiGene

$5.00

PackGene and Kudo Bio Partner to Provide End-to-End mRNA Services

$5.00

Canton Biologics Raises $41 Million in C Round for Biologic CDMO Services

$5.00

Clover Biopharma Starts China Distribution of Quadrivalent Seasonal Flu Vaccine

$5.00

Cure Genetics to Develop AAV Vectors for Neuro Startup in $60 Million Deal

$5.00

Dizal’s JAK1 Inhibitor NDA Accepted for China Review as PTCL Therapy

$5.00

Shanghai Pharma Signs MOU to Run China Phase III Trial of Korean Alzheimer’s Drug

$5.00

JW Therapeutics to Develop Two Additional 2seventy Cell Therapies in China

$5.00

Insilico Out-Licenses Global Rights for USP1 Inhibitor to Exelixis for $80 Million Upfront

$5.00

BioRay Approved to Launch Anruixi, a CD20 mAb, for B-Cell Lymphoma in China

$5.00

Hasten Biopharma Enters $325 Million Deal for PCSK9 Cholesterol Drug

$5.00

Sorrento Reports Positive Topline Results from China Trial of COVID Therapy

$5.00

ImmuneOnco Stages $30 Million Hong Kong IPO for Innate/Adaptive Immunity Drugs

$5.00

Biosyngen Approved for US Trials of TCR-T Candidate for Solid Tumor Cancers

$5.00

Neurophth to Begin Australian Trial of Gene Therapy for Visual Impairment

$5.00

Biocytogen Forms ADC Partnership with Myriex, a Cytotoxic Payload Company

$5.00

AnHeart Starts Global Phase II Trial of mIDH1 Inhibitor for Brain Cancer

$5.00

Gloria Bio Approved to Launch anti-PD-1 Drug for Metastatic Cervical Cancer

$5.00

Brii Bio Announces Positive Interim Results for Hepatitis B Therapeutic Vaccine

$5.00

Huadong Pharma Signs $52 Million China Deal for Topical Psoriasis Therapy

$5.00

ABM Therapeutics Begins China Phase I Trial of BRAF Inhibitor for Brain Tumors

$5.00

Kangpu Closes $13.8 Million B Round for Protein Ubiquitination Candidates

$5.00

DualityBio and BioNTech to Begin Phase III US Trial of ADC for Breast Cancer

$5.00

Biocytogen Re-organizes into Preclinical Service and Drug Discovery Divisions

$5.00

Genexine/I-Mab Announce Positive Results from Phase III Growth Hormone Trial

$5.00

InxMed Will Begin China Trial of FAPα Inhibitor to Lower Immunotherapy Resistance

$5.00

Asieris Starts China Trials of Dopamine Beta-Hydroxylase Inhibitor for Ulcerative Colitis

$5.00

Akeso Completes Phase III Trial Enrollment of PD-1/VEGF Bispecific for NSCLC

$5.00

Harbour BioMed to Start US Trials of its First ADC Candidate

$5.00

GenFleet Partners Three Pre-Clinical RAS Candidates with Verastem in $625.5 Million Deal

$5.00

Henlius Collaborates with HanchorBio to Develop Novel Immuno-Biologics

$5.00

China Consortium Aims to Acquire Drug Distributor in Poland

$5.00

AusperBio Approved to Start US Trials of Antisense Oligonucleotide for Hepatitis B

$5.00

Simcere Acquires Commercialization Rights to Mabpharm’s Colorectal Cancer Therapy

$5.00

Lynk Pharma Says JAK1 Inhibitor Effective for Ankylosing Spondylitis

$5.00

CirCode Raises “Millions of Dollars” in A Round for Circular RNA Drugs

$5.00

Dizal Approved to Launch EGFR Inhibitor for NSCLC with Exon 20 Mutations

$5.00

Hengrui Approved to Launch Antifungal for Vulvovaginal Candidiasis

$5.00

HutchMed’s Syk Inhibitor Meets Phase III Endpoints for Immune Thrombocytopenia

$5.00

Innovent Approved to Launch PCSK9 Inhibitor in China for High-Cholesterol

$5.00

CARsgen and Moderna to Test Dual Claudin18.2 Cancer Therapy Combo

$5.00

Sangon Raises $290 Million for Life Science Tools and Services Business

$5.00

Akeso Starts Phase III Trial of PD-1/VEGF Bispecific for NSCLC

$5.00

Hengrui Out-licenses Ex-China Rights to Asthma/Sinusitis Therapy in $1 Billion Deal

$5.00

CytoMed Signs MOU with CNK Therapeutics for Gene Grafting Technology in CAR Therapies

$5.00

China Announces Plans to Facilitate Foreign Investments in its Biopharma Industry

$5.00

OnCusp to Start US Trials of CDH6 ADC In-licensed from China’s Multitude

$5.00

Zhongmei Huadong In-licenses Skin Disease Therapy in $94 Million Agreement

$5.00

Kelun-Biotech’s Lead ADC Meets Endpoint in Phase III Triple Negative Breast Cancer Trial

$5.00

Antengene Signs up Hansoh in $101 Million Deal for Commercialization Rights to XPO1 Inhibitor

$5.00

Neurophth Closes $95 Million Series C+ Round for Gene Therapy Ophthalmology Therapies

$5.00

Jacobio Awarded China Breakthrough Status for KRAS Inhibitor in Pancreatic Cancer

$5.00

AceLink Starts China Phase II Trial of Novel GCS Inhibitor for Fabry Disease

$5.00

CanSinoBIO and AstraZeneca Form mRNA Vaccine Collaboration

$5.00

BioCity Approved to Start US Trial of Bispecific Antibody for Solid Tumors

$5.00

Investisbio Out-Licenses KRAS G12C Inhibitor to Sino Biopharm Subsidiary

$5.00

BeiGene’s Breakup with Celgene/BMS Now Complete with Return of BeiGene Shares

$5.00

Gracell Raises $100 Million in Private Placement for Trials of CAR-T Candidates

$5.00

Duality Biologics Adds Third ADC Candidate to BioNTech Partnership

$5.00

Mundipharma May Propose Sale of China Operations for $1 Billion

$5.00

LianBio Starts China Trials of SHP2 Inhibitor for NSCLC with EGFR Mutations

$5.00

Oramed and Hefei Tianhui to Form $60 Million JV for Oral Insulin Product

$5.00

Doer Biologics Starts Trial of Tri-Specific Drug for Obesity

$5.00

ABVC Out-licenses China Rights for Two Neurologic Therapies to Xinnovation

$5.00

CASI Acquires China Rights to Lymphoma Chemotherapy from Mundipharma

$5.00

CirCode Forms Partnership with Pfizer to Develop Circular RNA Therapeutics

$5.00

Xinkanghe Biomedical Raises $14 Million for Immunology Drugs

$5.00

Leads Biolabs Approved to Start China/US Trials of Bispecific for Multiple Myeloma

$5.00

Transcenta to Start Phase II Trial of Osteoporosis Therapy in China

$5.00

Mirxes Closes $50 Million Round for miRNA Tests; Will IPO in Hong Kong

$5.00

RemeGen Publishes Data Showing Telitacicept Effective for Sjögren's Syndrome

$5.00

Pyrotech Closes $97 Million Round to Develop Novel Technology for Autoimmune and Cancer Drugs

$5.00

Everest Launches Novel Antibiotic in China for Difficult/Drug Resistant Infections

$5.00

Viage Says Zhongze-Partnered Gut-Based Therapy Effective for Cognitive Decline

$5.00

SunHo Bio Starts China Trials of Immunocytokine for Solid Tumor Cancers

$5.00

Pillar Bio Partners with Illumina to Offer Genomic Profiling Assays for Oncology

$5.00

Ascletis Says PD-L1/Chidamide Combination May Offer Cure for HIV

$5.00

MindRank Raises $20 Million in A+ Round to Support AI Drug Development Operations

$5.00

Overland ADCT Says Zynolonta BLA Accepted for China Review as Lymphoma Therapy

$5.00

CASI Pharma Acquires VCP/p97 Inhibitor for Myeloid Leukemia and MDS

$5.00

Qihan Starts Trial of Gene-Edited iPSC-Derived NK Cell Therapy for Leukemia

$5.00

Triastek 3D-Printed Candidate Delivers Active Ingredient to Ulcerative Colitis Target

$5.00

Novartis in $1 Billion Deal for DTx Pharma, an siRNA Company Incubated by Viva BioInnovator

$5.00

Fosun Kite Approved to Launch CAR-T as Second Line Therapy for B-Cell Lymphoma

$5.00

Antengene Doses First Patient in Trial of ERK1/2 Inhibitor Combined with BMS’s PD-1

$5.00

HighField Biopharma Starts China Trial of Immune Modulating Liposome for Glioma

$5.00

Kelun-Biotech Raises $174 Million in Hong Kong IPO for ADC Portfolio

$5.00

GeneQuantum Licenses Novel Bioconjugation Technology to InxMed

$5.00

Beijing InnoCare Plans Combined Therapy with Arrivent for NSCLC

$5.00

Connect Reports Progress in Next-gen IL-4Rα Antibody for Atopic Dermatitis

$5.00

GeneQuantum Adds Five ADC Candidates to its Collaboration with Aimed, a Korean Biotech

$5.00

Fosun Pharma Files China NDA for Hyperphosphatemia Therapy in Dialysis Patients

$5.00

Biosyngen to Establish Guangzhou-Singapore Translational Center for Cancer Drugs

$5.00

Sinotau Pharma Completes $152 Million E Round for Radiopharmaceutical Portfolio

$5.00

280Bio, a Yingli Pharma Subsidiary, to Start US Trials of RAS Inhibitor

$5.00

BeiGene Options ADC for Solid Tumor Cancer from Duality Bio in $1.3 Billion Deal

$5.00

WuXi Biologics Plans Spin-off and $500 Million Hong Kong IPO of Conjugates Subsidiary

$5.00

Sirnaomics Provides Capital and RNA Delivery Technology to EDIRNA, an RNA Editing Company

$5.00

Shanghai’s Skyline Approved to Start US Trial of Gene Therapy for Macular Degeneration

$5.00

Brii Bio Expands Rights for VBI’s HBV Therapy to Global in $437 Million Deal

$5.00

Hansoh Pharma to Start China Trials of Novel Endometriosis Therapy

$5.00

F-star Signs Third Collaboration with Takeda; This One is Worth up to $1 Billion

$5.00

Shanghai Wong Pharma Raises $152 Million for Allergy and Autoimmune Candidates

$5.00

Zai Lab Approved to Launch Fc Receptor Agonist for Myasthenia Gravis Patients

$5.00

Kelun-Biotech to Raise up to $208 Million in Hong Kong IPO for ADC Portfolio

$5.00

AusperBio to Start China Trials of Antisense Oligonucleotide for Chronic Hepatitis B Cure

$5.00

Laekna Raises $100 Million in Hong Kong IPO for Cancer, Liver Fibrosis Inhibitors

$5.00

BCHT Bio Pays $21 Million for 20% Stake in mRNA Vaccine Company; Will Acquire the Rest

$5.00

CBMG Out-Licenses Top Two CAR-T Candidates to Janssen for $245 Million Upfront

$5.00

CStone RET Inhibitor Approved in China for First-Line Treatment in NSCLC Patients

$5.00

Lion TCR Raises $40 Million to Develop HBV-Specific T Cell Receptor Therapy for Liver Cancer

$5.00

Insilico Starts China-US Phase II Trials of AI-Discovered Therapy for Lung Fibrosis

$5.00

Brii Bio to Receive $24 Million from Sale of Qpex; Gains Global License to Anti-Infective

$5.00

Innovent Collaborates with RemeGen to Test PD-1/ADC Combination for Solid Tumors

$5.00

Edding Group Files for Hong Kong IPO to Support its China In-licensing Operations

$5.00

Everest Medicines Reports In-licensed Candidate Effective for Rare Kidney Disease

$5.00

BioCity Starts China Phase II Trial of ETA-Receptor Antagonist for Kidney Disease

$5.00

WestGene Biopharma Raises $42 Million in a Series A Funding for its mRNA Portfolio

$5.00

Minghui Starts Clinical Trials for Two Novel ADCs Aimed at Solid Tumor Cancers

$5.00

AstraZeneca May Create New Company for China Ops and List in Hong Kong or Shanghai

$5.00

Cutia Therapeutics Raises $65 Million in Hong Kong IPO for Dermatology Products

$5.00

Cullgen Forms $1.9 Billion Collaboration with Astellas for Protein Degraders

$5.00

Cholesgen Collaborates with AstraZeneca to Develop Hypercholesterolemia Candidates

$5.00

HighField Bio to Start US Trial of Immunoliposome for Solid Tumor Cancers

$5.00

Genor Biopharma’s PD-1 Drug Nixed by China Regulators for Rare Lymphoma

$5.00

Simcere to Underwrite up to Eight Research Projects at Mass General Brigham

$5.00

China Medical System’s Novel Nasal Spray Approved to Treat Seizures in China

$5.00

Innovent’s anti-CD47/PD-L1 Bispecific Antibody Effective in Hodgkin Lymphoma

$5.00

Ractigen Starts China Trials of siRNA Candidate for ALS Patients

$5.00

HighTide Plans Hong Kong IPO to Support Metabolic and Digestive Portfolio

$5.00

WestVac Biopharma Approved to Launch COVID-19 Vaccine for XBB Variants

$5.00

Fosun Pharma Lands $107 Million to Build African Production and Distribution Facility

$5.00

Innovent/IASO Release Strong Long-Term Data on CAR-T for Multiple Myeloma

$5.00

iTabMed Approved to Start China Trials of CD3 Bi-specific for Solid Tumors

$5.00

Dizal Updates Clinical News of its Two Global Trial Assets at ASCO

$5.00

ASCO: BioNTech and Merck Present Positive Data on China-Sourced Oncology Drugs

$5.00

Gracell Reports Positive Data from Trial of BCMA/CD19 FasTCAR-T in Multiple Myeloma

$5.00

CANbridge Approved to Launch Pruritus Therapy for Alagille Syndrome in China

$5.00

Connect Reports UC Therapy Offers Statistically Significant Improvement

$5.00

Impact Sells Rights for Two PARP Inhibitors to Eikon Therapeutics

$5.00

invoX Makes 2nd Investment in pHion, a Belfast mRNA Vaccine Company

$5.00

Lynk Pharma Closes C1 Round with $28 Million for Oncology and Autoimmune Drugs

$5.00

HighField Biopharma Reports Progression-Free Survival in Glioma Patients

$5.00

Betta Signs $392 Million Agreement for Lung Cancer Drug with C4 Therapeutics

$5.00

Unicar-Therapy Publishes Positive Data for Dual-Target CAR T-cell Leukemia Therapy

$5.00

ProfoundBio Provides Updates on Two ADC Candidates in US-China Trials

$5.00

Ascentage Details ASCO Abstracts for Four Novel Cancer Drugs

$5.00

Lynk Doses First Cohort of Psoriasis Patients with Topical Third-Gen JAK Inhibitor

$5.00

Accropeutics to Start Phase I Trial of TYK2/JAK1 Inhibitor for Psoriasis

$5.00

Allgenesis Reports Positive Data from US Trial of Diabetic Macular Edema Therapy

$5.00

BioRay to Start Trials of LIV-1 Targeting ADC for Advanced Malignant Tumors

$5.00

Antengene Awarded Orphan Status for Claudin 18.2 ADC in Two Cancer Indications

$5.00

Minghui Pharma Doses First Subject in Phase I Trial of Autoimmune Candidate

$5.00

Laekna to Start Phase I/II Trials of ATP Inhibitor in US for Lung Cancer

$5.00

HanxBio Approved to Start US Trials of anti-CD47/PD-1 for Lymphoma

$5.00

CARsgen Starts US Phase II Trial of CLDN18.2 CAR-T for Gastric Cancer

$5.00

Boan Bio Approved to Start Trials of Bispecific Antibody for CEA Solid Tumor Cancers

$5.00

Hengrui Affiliate Files for US Approval of PD-1 in Early Liver Cancer

$5.00

CANbridge Reports Data From Preclinical Test of Gene Therapy for Spinal Muscular Atrophy

$5.00

Coherent Bio Closes B Round with $100 Million for XDC Candidates

$5.00

Coherent Bio Closes B Round with $100 Million for XDC Candidates

$5.00

Keymed and Rona Partner to Discover siRNA Drugs for Severe Kidney Disease

$5.00

Amoytop and Aligos Team Up in $109 Million Deal to Develop Novel Drugs for Liver Diseases

$5.00

Drug Farm Raises $27 Million for AI-based Immune-modulating Therapies

$5.00

LaNova of Shanghai Sells Myeloma ADC Rights to AstraZeneca for $600 Million

$5.00

Gracell Announces Trial of FasTCAR Candidate in Autoimmune Diseases

$5.00

Innovent Reports Positive Data from GLP-1R/GCGR Agonist in Weight Loss Trial

$5.00

Chance Pharma Acquires China Rights for Inhaled Parkinson’s Therapy in $144 Million Deal

$5.00

GenAssist Says US IND Accepted for Base Editing Product in Duchenne Muscular Dystrophy

$5.00

Suzhou Zion Out-Licenses Brain-Penetrating HER2 Candidate to Roche in $680 Million Deal

$5.00

EQRx Gives up on In-licensing Drugs from China for Lower Cost Therapies in the West

$5.00

Bliss Biopharma Out-Licenses HER2 ADC to Eisai for up to $2 Billion

$5.00

Junshi Signs $728 Million Deal Granting Rights for Anti-PD-1 in 21 Countries to Dr. Reddy’s

$5.00

Janssen In-licenses CAR-Ts for $245 Million Upfront, its 2nd CAR-T Deal with a China Biotech

$5.00

Zai Lab Acquires Global Rights to ADC for Small Cell Lung Cancer from MediLink

$5.00

Adcentrx, a San Diego-Shanghai Company, Raises $38 Million for ADC Portfolio

$5.00

Hasten Bio of Hefei Raises $315 Million for Product Acquisitions

$5.00

CARsgen CAR-T Approved to Start China Trials for Pancreatic Cancer

$5.00

Pfizer Partners with Sinopharm to Bring 12 Innovative Drugs to China

$5.00

XtalPi/Merck Collaboration Uses AI + Wet Lab to Improve Crystal Morphology

$5.00

Junshi Bio’s PARP Inhibitor Effective as Maintenance Therapy for Ovarian Cancer

$5.00

Bridge Bio Doses First Patient in Phase II Trial of ATX Inhibitor for Fibrosis

$5.00

VintaBio Opens Cell and Gene Therapy CDMO after $64 Million Round led by Decheng

$5.00

Sirnaomics Starts US Phase I Trial of RNAi Anticoagulant

$5.00

OnCusp to Post Data on Lead Candidate, an Anti-CDH6 ADC

$5.00

Genor Reports CDK4/6 Inhibitor NDA Under Review in China for Breast Cancer

$5.00

JW Therapeutics Starts China Trial of CAR-T for Systemic Lupus Erythematosus

$5.00

Mabwell Says Nectin-4 ADC Posts Positive Results in Solid Tumor Cancers

$5.00

Evopoint to Start China Trial of EZH2 Inhibitor Combined with Merck/MSD’s Keytruda

$5.00

InnoCare Doses First Patient in Trial of Protein Degrader for Myeloma and Lymphoma

$5.00

Pierre Fabre Enters $618 Million Deal with Boston’s Scorpion for Two Novel EGFR Candidates

$5.00

Biosion USA to Start US Phase II Trials of Novel Candidate for Asthma

$5.00

Lynk Pharma Reports Third-Gen JAK Inhibitor Meets Safety Goals in Phase I Trial

$5.00

HutchMed Completes US Filing of Fruquintinib for Metastatic Colorectal Cancer

$5.00

DualityBio Sells Two ADC Assets to BioNTech for $170 Million Upfront, $1.5 Billion in Milestones

$5.00

Mabwell Approved to Launch Biosimilar to Amgen's Osteoporosis Therapy in China

$5.00

Mabwell Approved to Launch Biosimilar to Amgen's Osteoporosis Therapy in China

$5.00

Apollomics Merges with SPAC to List on NASDAQ; Climbs 121% Higher in Trading

$5.00

Ablaze Pharma Acquires China Rights to Targeted Radiotherapy Drug for Liver Cancers

$5.00

SciNeuro Signs Up Secarna to Discover Antisense Oligonucleotide Therapies for Neurology Targets

$5.00

ImmVira Approved to Start Trials of Oncolytic Virus Candidate for Malignant Glioma

$5.00

Pharmaron Receives $186 Million Grant to Expand UK Cell/Gene Therapy Manufacturing

$5.00

Junshi Forms Commercialization JV with Rxilient to Market PD-1 in Southeast Asia

$5.00

SalubrisBio Reports $35 Million Infusion from Parent for Novel Biologic Drugs

$5.00

OncoVent Sells Taiwan Rights to Ovarian Cancer Candidate for $11 Million

$5.00

ArriVent Closes $155 Million Round to In-license US Rights for China Drugs

$5.00

YS Biopharma Says PIKA COVID-19 Vaccine Offers Superior Immunogenicity

$5.00

Everest Forms Renal Research Partnership with Guangdong Medical Academy

$5.00

F-star Partners Second Early-Stage Tetravalent Bispecific Antibody with Takeda

$5.00

Transcenta Starts US Trials of Gremlin1 mAb for Prostate and Colorectal Cancer

$5.00

Highlightll Out-licenses Dual Inhibitor for Parkinson’s in $970 Million Deal

$5.00

Joincare to Develop TaiGen’s Pan-Flu Therapy in Greater China

$5.00

Boan Biotech Files China BLA for Bone Metastases Biosimilar

$5.00

280Bio Showcases Preclinical Findings for Novel KRAS Inhibitor

$5.00

Connect Biopharma’s IL-4Rα Antibody Effective in Atopic Dermatitis Patients

$5.00

Gracell Closes Cell Therapy Deal with Seagen; No Details Released

$5.00

ArkBio and Scripps Research Extend Partnership for Novel Respiratory Candidate

$5.00

Base Biotech Raises “Tens of Millions of Dollars” in A1 Round for Base Editing

$500.00

Everest Approved to Launch Antibiotic in China for Intra-Abdominal Infections

$5.00

Mabwell Starts Trials of mAb to Regulate Iron Homeostasis In Vivo

$5.00

Simcere to Test TNRF2 mAb in Combination with MSD’s Keytruda for Solid Tumors

$5.00

Everest’s In-licensed Kidney Drug Meets Endpoints in Phase III Trial

$5.00

Bio-Thera Starts Phase I Trial of Nectin-4 ADC for Solid Tumors

$5.00

Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million

$5.00

Luye Enrolls Last Patient in Phase III Trial of Eylea Biosimilar

$5.00

Allorion Raises $50 Million for Oncology/Autoimmune Precision Medicines

$5.00

AusperBio Starts New Zealand Phase I Trial of Novel Therapy for CHB

$5.00

Ambrx Partner Says HER2 ADC Ups Progression-Free Survival in Breast Cancer Trial

$5.00

Ractigen Granted Orphan Drug Status for Use of Novel siRNA in ALS

$5.00

CFIUS Approves Sino Biopharm’s Acquisition of F-Star after Nine Month Wait

$5.00

JW Therapeutics Announces CAR-T Trial as First-Line B-Cell Lymphoma Therapy

$5.00

JW Therapeutics Announces CAR-T Trial as First-Line B-Cell Lymphoma Therapy

$5.00

Rinua Gene Raises $14.5 Million in Pre-A+ Round for mRNA Drugs

$5.00

Harbour BioMed mAb Posts Positive Results in Phase III Myasthenia Gravis Trial

$5.00

JW Therapeutics Starts China Trial of T-cell Immunotherapy for Liver Cancer

$5.00

Transcenta Reports Immuno-PET Diagnoses CLDN18.2 Levels in Gastrointestinal Tumors

$5.00

Abbisko Out-Licenses Precision EGFR-TKI Medicine to Allist in $188 Million Deal

$5.00

TandemAI Raises $35 Million for AI/WetLab Drug Discovery Operations

$5.00

Immorna Raises $100 Million for Clinical Trials of Novel RNA Candidates

$5.00

Atom Bioscience Says Gout Treatment Meets Phase II Efficacy/Safety Endpoints

$5.00

Shanghai Oricell Raises $45 Million to Take Cellular Immunotherapies to US

$5.00

Junshi Reports anti-PCSK9 mAb Lowers Cholesterol in Phase III Trials

$5.00

Kelun Biotech Plans Hong Kong IPO to Develop ADCs and Other Products

$5.00

Chipscreen Signs $72 Million Deal for Eucure Bispecific Immunotherapy

$5.00

BeiGene’s PD-1 Approved in China for Tenth Indication, Gastric Cancer

$5.00

InnoCare-Keymed JV Starts China Trial of Novel CCR8 Immunotherapy

$5.00

Keymed-Lepu JV Out-Licenses Claudin 18.2 ADC to AstraZeneca in $1.2 Billion Agreement

$5.00

Accutar Starts China Trial of Oral Chimeric Degrader for Prostate Cancer

$5.00

Kinnate, a Precision Oncology Company, Pays $24 Million to Buy Out JV Partners

$5.00

Shenzhen Fapon Bio Starts US Trial of CD47 mAb for Advanced Malignancies

$5.00

InnoCare’s $937 Million MS Deal Falls Apart as Biogen Returns Rights

$5.00

Neurophth Completes Dosing in Phase III Trial of Gene Therapy for Hereditary Blindness

$5.00

Frontera Therapeutics Begins Trials for Three Leading Gene Therapy Candidates

$5.00

Innovent Starts China Trial of Novel mAb as Extended-Dose Psoriasis Therapy

$5.00

Junshi/Coherus Report PD-1 Effective in US Trial for Nasopharyngeal Carcinoma

$5.00

Henlius Biotech Reports US Accepts Herceptin Biosimilar BLA for Review

$5.00

Harbour BioMed Out-Licenses US Rights for Bispecific in $588 Million Deal

$5.00

Clover Launches COVID-19 Vaccine in China as Second Booster Dose

$5.00

CSPC Pharma Out-Licenses Nectin-4 ADC to Corbus in $692 Million Deal

$5.00

Wondercell Closes $14 Million in Angel Funding for Immune Cell Therapies

$5.00

Boan Biotech Starts China Trial of Anti-CD25 Antibody for Solid Tumor Cancers

$5.00

CANbridge Acquires Global Rights to Rare Disease Therapy from UMass

$5.00

ImmVira Posts Positive Data from Trial of Oncolytic Virus Injection for Melanoma